氨基葡萄糖
骨关节炎
软骨素
保健品
硫酸软骨素
药理学
医学
透明质酸
化学
生物化学
糖胺聚糖
病理
解剖
替代医学
作者
Carlo Bottegoni,Riccardo A.A. Müzzarelli,Francesca Giovannini,Alberto Busilacchi,Antonio Gigante
标识
DOI:10.1016/j.carbpol.2014.03.033
摘要
Oral supplementation of chondroitin sulphate plus glucosamine helps repair the articular surface in osteoarthritis. Chondroitin-S reduces the concentration of the pro-inflammatory cytokines and transcription factor involved in inflammation. GlcN.S enhances cartilage specific matrix components and prevents collagen degeneration in chondrocytes by inhibiting hydrolytic enzymes, and preventing the oxidation of lipids and proteins. Chondroitin-S plus GlcN.S are slow-acting drugs that alleviate pain and partly restore joint function in OA patients. Orally administered pharmaceutical-grade chondroitin-S plus GlcN.S stabilize the joint space narrowing and significantly decrease the number of patients with new erosive OA. They are safe and no adverse events have ever been reported; they are recommended by EULAR and OARSI. The cost/effectiveness of the oral chondroitin-S plus GlcN.S therapy derives from the reduction of costs for physiotherapy, and for gastroprotective and non-steroidal drugs. The synergistic association of these two world-widely preferred nutraceuticals is a step forward in the management of OA.
科研通智能强力驱动
Strongly Powered by AbleSci AI